Wyss InstituteMicrotechnology – Wyss Institute

Nucleic Acid Delivery Consortium

Mariel Schoen — Fri, 13 Mar 2026 15:13:09 +0000

Nucleic acid therapies are emerging as a revolutionary class of medicines. Using engineered DNA or RNA molecules, they treat diseases at their genetic source, thus offering potential cures for a large variety of disorders, ranging from genetic disorders to cancers and infectious diseases. Different technologies, including mRNA, short interfering RNAs (siRNA), antisense oligonucleotides (ASOs)…

Source

Blood Clot Dx

admin — Wed, 09 Jul 2025 17:00:40 +0000

Blood clots can arise anywhere in the body, blocking blood flow and causing pain and other symptoms. The most serious types of clots, called deep vein thrombosis (DVT), typically form in the veins in the legs, and can break off and become lodged in a lung. This can cause a pulmonary embolism (PE), which is when blood flow to the lungs is prevented and can be fatal. The symptoms of PE resemble…

Source

Precision oncology Organ Chip platform accurately and actionably predicts chemotherapy responses of patients suffering from esophageal adenocarcinoma

Jessica Leff — Fri, 27 Jun 2025 13:20:57 +0000

By Benjamin Boettner (BOSTON) — Esophageal adenocarcinoma (EAC), one of two major forms of esophageal cancer, is the sixth most deadly cancer worldwide for which no effective targeted therapy exists. Patients need to rely on chemotherapy as a standard-of-care, which is started ahead of surgical interventions as a so-called “neoadjuvant chemotherapy” (NACT) in the hope to shrink or control tumors.

Source

The Wyss Institute’s 2024-2025 Validation Projects

Jessica Leff — Wed, 29 May 2024 14:55:23 +0000

Every year the Wyss Institute names a class of Validation Projects whose teams receive dedicated funding, business development support, and other resources to advance their promising technologies towards commercialization. They also collaborate with key opinion leaders, investors, and potential customers to de-risk their innovations and speed their progress to the market. This year…

Source

Paper-Based Diagnostics

admin — Wed, 01 May 2024 00:34:41 +0000

With the imminent threat of new pandemics and frequent disease outbreaks exemplified by the recent Ebola and Zika epidemics, there is a growing need for low-cost, easily deployable and simple-to-use diagnostic tools. The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient care. This new type of…

Source

Passive Directional Valve Technology: Towards More User-friendly and Accessible Microfluidic Devices for Diagnostic and Research Applications

Jessica Leff — Fri, 12 Jan 2024 17:42:46 +0000

Automated fluid-transporting and processing systems that function on the scale of micrometers (microfluidic systems) are becoming increasingly important for advancing various diagnostic, drug fabrication and delivery, and tissue engineering applications. Efforts to create smaller microfluidic devices with functionalities realized at larger scales rely heavily on valves to enable the regulated…

Source

The Vagina Chip: A New Preclinical Model for Research on Vaginal Epithelium Microbiome Interactions

Jessica Leff — Mon, 28 Nov 2022 19:33:14 +0000

The Vagina Chip allows researchers to study a human model of the vaginal microbiome and develop new treatments for bacterial vaginosis and other conditions that threaten women’s health. Credit: Research Square…

Source

A breakthrough in bacterial vaginosis treatment for women’s health

Mariel Schoen — Mon, 28 Nov 2022 18:56:46 +0000

By Lindsay Brownell (BOSTON) — The human microbiome has been a hot topic over the last decade, with research pointing to disrupted bacterial communities as culprits for a host of maladies including irritable bowel syndrome, eczema, and autoimmune diseases. Most studies have focused on the microbiome within the human gut, but there is growing recognition that another oft-ignored bacterial…

Source

New portable diagnostic detects SARS-CoV-2 RNA and antibodies at the same time

Jessica Leff — Mon, 08 Aug 2022 14:58:32 +0000

By Lindsay Brownell (BOSTON) — As the COVID-19 pandemic has run its course, the questions we have been asking ourselves have evolved: from “How do I know if I’m infected?” to “How strong is my immunity?” to “Which strain of the virus do I have?” And, as new variants continue to emerge, it’s likely that we’ll keep asking ourselves those questions, often at the same time. Now, there’s a way to…

Source

Cantex licenses intellectual property from Harvard University to develop repurposed drug identified by Wyss Institute to treat inflammatory lung diseases including COVID-19

Jessica Leff — Wed, 23 Feb 2022 15:57:42 +0000

By Lindsay Brownell (BOSTON, MA and WESTON, FL) – Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Weston, FL, and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that Cantex has secured a global license from Harvard University’s Office of Technology Development (OTD) to develop azeliragon, a small-molecule drug in…

Source